Clinical trial
A Phase 2, Randomised, Single-masked, Active-controlled, Multicentre Study to Evaluate the Efficacy and Safety of Intravitreal THR-317 Administered in Combination With Ranibizumab, for the Treatment of Diabetic Macular Oedema (DME)
NCT03499223 is registered in ClinicalTrials.gov with Oxurion as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomised, Single-masked, Active-controlled, Multicentre Study to Evaluate the Efficacy and Safety of Intravitreal THR-317 Administered in Combination With Ranibizumab, for the Treatment of Diabetic Macular Oedema (DME)
- Lead sponsor
- Oxurion
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 20, 2018
- Completion date
- July 18, 2019
- Enrollment
- 70 (actual)
- Sites
- 37
Conditions
As the registry lists them; a condition with its own page is linked.